Advertisement

Reactions Weekly

, Volume 1786, Issue 1, pp 135–135 | Cite as

Pembrolizumab

Development of resistance in metastatic cutaneous squamous cell carcinoma and off-label treatment: case report
Case report
  • 9 Downloads

Reference

  1. Zalaudek I, et al. Patterns of response and acquired resistance to the programmed death-1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma. Dermatologic Therapy 32: No. 6, Nov-Dec 2019. Available from: URL: http://doi.org/10.1111/dth.13107

Copyright information

© Springer International Publishing AG 2020

Personalised recommendations